Hyperuricemia with consequent monosodium urate crystal deposition leads to gout,
characterized by painful, incapacitating inflammatory arthritis flares that are also associated …

This article is published as part of a supplement sponsored by Kidney Disease: Improving
Global Outcomes (KDIGO). The opinions or views expressed in this supplement are those of …

Introduction Hyperuricemia is an overlooked cardiovascular and renal risk factor.
Epidemiological and genetic studies have shown an independent role of uric acid in the risk …

Objective In gout, hyperuricemia promotes urate crystal deposition, which stimulates the
NLRP3 inflammasome and interleukin‐1β (IL‐1β)–mediated arthritis. Incident gout without …

Gout and hyperuricaemia are two clinical situations associated with an elevated risk of
develo** cardiovascular (heart failure, myocardial infarction, stroke) and metabolic and …

Uric acid is a toxin retained with advancing kidney disease. Clinical manifestations of
hyperuricemia include gout and systemic inflammation that are associated with increased …

Importance Clinicians often approach urate-lowering therapy (ULT) cautiously in patients
with gout and impaired kidney function because they are concerned about the risk of …

Xanthine oxidase, a molybdo-flavoenzyme, and an isoform of xanthine dehydrogenase both
exist as xanthine oxidoreductase and are responsible for purine catabolism. Xanthine …

Background: Hyperuricemia is associated with elevated risks of cardiovascular and chronic
kidney disease (CKD). Since inhibition of urate transporter 1 has been suggested to be …

Gout, a common form of inflammatory arthritis, is characterized by deposition of monosodium
urate crystals in articular and periarticular tissues. Repeated flares of gout cause joint …